Brief: Eagle Pharmaceuticals Says Co Expects To Revise Its Previously Disclosed 2023 Full Year Guidance Downward
09/11/2023 13:22
Nov 9 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS INC - COMPANY EXPECTS TO REVISE ITS
PREVIOUSLY DISCLOSED 2023 FULL YEAR GUIDANCE DOWNWARD
* EAGLE PHARMACEUTICALS - REQUIRES MORE TIME TO REVIEW
POTENTIAL
ADJUSTMENTS RELATING TO THE REPORTING OF SALES OF PEMFEXY® PRIOR
TO FILING FORM 10-Q
Further company coverage: EGRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq